Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees. The enlarged entity will retain the Synexus name.
“We are delighted to be working together with the Radiant team,” said Christophe Berthoux, who has been chief executive officer for Synexus since 2010 and will lead the new company. “Best practices from Synexus, Radiant and our earlier acquisition of Research Across America will be incorporated across our global network of sites.”
Mike Clay will lead the U.S. operations of the combined business, reporting directly to Berthoux.
The new business will span 11 countries, offering access to more than 100 million patients in clinical development markets, and it will provide data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe and Africa, according to Synexus.
Philip Ward is the European Editor for Applied Clinical Trials
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.